DrugPatentWatch Database Preview
Drugs in Development Information for Tegafur
» See Plans and Pricing
What is the development status for investigational drug Tegafur?
Tegafur is an investigational drug.
There have been 129 clinical trials for Tegafur.
The most recent clinical trial was a Phase 3 trial, which was initiated on June 1st 2013.
The most common disease conditions in clinical trials are Stomach Neoplasms, Colorectal Neoplasms, and Carcinoma. The leading clinical trial sponsors are Fudan University, National Taiwan University Hospital, and Taiho Oncology, Inc.
There are two US patents protecting this investigational drug and twenty-seven international patents.
Summary for Tegafur
| US Patents | 2,107 |
| International Patents | 27,136 |
| US Patent Applications | 3,928 |
| WIPO Patent Applications | 2,697 |
| Japanese Patent Applications | 3 |
| Clinical Trial Progress | Phase 3 (2013-06-01) |
| Vendors | 66 |
Recent Clinical Trials for Tegafur
| Title | Sponsor | Phase |
|---|---|---|
| A Phase II Study of Gimatecan (ST1481) in Locally Advanced or Metastatic Pancreatic Cancer | Lee's Pharmaceutical Limited | Phase 2 |
| Adjuvant Chemotherapy in Combination With Camrelizumab for Stage III Gastric Cancer (FOCUS-02) | Yu jiren | Phase 2 |
| Nivolumab Adding on Gemcitabine/S-1 in Metastatic Pancreatic Cancer | ACT Genomics | Phase 2 |
Clinical Trial Summary for Tegafur
Top disease conditions for Tegafur
Top clinical trial sponsors for Tegafur
US Patents for Tegafur
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Tegafur | Start Trial | Heterocyclic compound | Takeda Pharmaceutical Company Limited (Osaka, JP) | Start Trial |
| Tegafur | Start Trial | Nuclear targeting sequences | Yeda Research and Development Co. Ltd. (Rehovot, IL) | Start Trial |
| Tegafur | Start Trial | Method of diagnosing and treating cancer using B-catenin splice variants | The United States of America, as represented by the Secretary, Department of Health & Human Services (Washington, DC) | Start Trial |
| Tegafur | Start Trial | Constructs containing multiple expression cassettes for cancer therapy | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (Jerusalem, IL) | Start Trial |
| Tegafur | Start Trial | Substituted indole Mcl-1 inhibitors | Vanderbilt University (Nashville, TN) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Tegafur
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Tegafur | Canada | CA2961033 | 2034-09-11 | Start Trial |
| Tegafur | European Patent Office | EP3192791 | 2034-09-11 | Start Trial |
| Tegafur | Japan | JPWO2016039408 | 2034-09-11 | Start Trial |
| Tegafur | World Intellectual Property Organization (WIPO) | WO2016039408 | 2034-09-11 | Start Trial |
| Tegafur | European Patent Office | EP2134373 | 2027-02-28 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
